Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2023-06-21 Regulatory Filings
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
IBT fortsätter rekrytera för tidigt födda barn till The Connection Study efter planerad säkerhetsanalys
Regulatory Filings Classification · 95% confidence The document is a press release from Infant Bacterial Therapeutics (IBT) announcing the results of a safety analysis by the Data Monitoring Committee (DMC) regarding their ongoing Phase III clinical trial. It provides an update on clinical progress and regulatory status rather than financial results, governance, or shareholder meetings. As it is a general regulatory announcement regarding company operations and clinical trial status that does not fit into specific categories like M&A or Earnings, it is classified as a general regulatory filing.
2023-06-21 Swedish
IBT offentliggör prospekt
Capital/Financing Update Classification · 98% confidence The document is a press release from Infant Bacterial Therapeutics AB (IBT) announcing the publication of a prospectus ('prospekt') related to a rights issue ('förtryckesemission'). It details the timeline for the rights issue, names the advisors, and includes extensive disclaimers regarding the prospectus and offering restrictions in various jurisdictions (USA, Australia, UK, EES). The key action is the announcement that the prospectus has been approved by the Swedish Financial Supervisory Authority (Finansinspektionen) and is now available. Since the document is an announcement about a financing/capital event (rights issue) and the associated legal documentation (prospectus), it strongly aligns with the 'Capital/Financing Update' category (CAP). It is not the prospectus itself, but the announcement of its publication, making CAP more specific than the general 'RPA' or 'RNS'.
2023-06-13 Swedish
IBT publishes prospectus
Capital/Financing Update Classification · 98% confidence The document is titled "IBT publishes prospectus" and explicitly discusses the publication and registration of a Swedish language prospectus in connection with a 'Rights Issue'. It details the timetable for the Rights Issue (record date, subscription period, final outcome announcement) and mentions that the prospectus was approved by the Swedish Financial Supervisory Authority. This content relates directly to a capital raising/financing activity (Rights Issue) and the associated official documentation (Prospectus). While a prospectus is a key document, the text itself is a press release announcing its availability and the details of the offering. This strongly aligns with the definition of 'Capital/Financing Update' (CAP), as it is the primary announcement detailing the terms and timeline of the capital raise. It is not a general regulatory filing (RNS) because it is highly specific to financing, nor is it a Report Publication Announcement (RPA) because it contains substantive details about the financing event itself, not just a notice that a report is available.
2023-06-13 English
Extraordinary General Meeting of Infant Bacterial Therapeutics
Share Issue/Capital Change Classification · 99% confidence The document explicitly discusses resolutions passed at an Extraordinary General Meeting (EGM) concerning a rights issue (share capital increase). While it details the mechanics of the capital raise, the primary context is the shareholder meeting resolution. The closest fit among the provided codes is 'AGM-R' (AGM Information), as EGMs are functionally similar to AGMs regarding shareholder resolutions, although 'CAP' (Capital/Financing Update) is also relevant due to the rights issue details. However, since the text is structured around the outcome of a general meeting ('Extraordinary General Meeting... it was resolved to approve...'), AGM-R is the most precise classification for the context of the meeting's outcome, even if the subject matter is capital change. Given the document's focus on the meeting resolution, AGM-R is selected over CAP.
2023-06-09 English
Extra bolagsstämma i Infant Bacterial Therapeutics
Capital/Financing Update Classification · 98% confidence The document text details the decisions made at an Extraordinary General Meeting (Extra bolagsstämma) regarding a rights issue (företrädesemission) involving the issuance of new shares (aktiekapital ska ökas genom emission av nya aktier). This action directly relates to changes in the company's capital structure and fundraising activities. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate classification for announcements concerning share issues and capital structure changes, even though it stems from a shareholder meeting. The document is not a full annual report (10-K), an earnings release (ER), or a general proxy statement (DEF 14A/PSI), but specifically addresses a capital event.
2023-06-09 Swedish
Notice of Extraordinary General Meeting of Infant Bacterial Therapeutics
AGM Information Classification · 99% confidence The document is explicitly titled "Notice of Extraordinary General Meeting of Infant Bacterial Therapeutics". It details the date, time, location, procedures for participation (in person or by advance voting), proposed agenda items (including election of Chairman and approval of a share issue), and shareholder rights related to the meeting. This content directly corresponds to the purpose of materials distributed to shareholders in preparation for a general meeting, which aligns best with the definition of materials related to an Annual General Meeting (AGM-R), even though this is an Extraordinary General Meeting (EGM). The key elements are the notice, the agenda, and voting instructions.
2023-05-16 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.